Kymera reports limited SVB exposure of $2.2M cash and $4.5M letter of credit

Kymera Therapeutics, Inc.

As of March 10, 2023, Kymera holds $2.2M cash at Silicon Valley Bank (SVB) and $4.5M restricted cash letter of credit.
Total cash and equivalents reported at $560M as of Dec 31, 2022; SVB exposure represents <1% of cash.
Company does not anticipate any material impact on operations or liquidity from SVB closure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.